Please ensure Javascript is enabled for purposes of website accessibility

Investing $100,000 Into These 2 Stocks 10 Years Ago Would Have Made You a Millionaire Today

By David Jagielski – Nov 22, 2021 at 7:00AM

Key Points

  • Shares of Seagen and Apple have soared more than 1,000% in the past 10 years.
  • A decade ago, Seagen was coming off an approval from the FDA for one of its drugs and was on its way to generating some incredible growth numbers.
  • Apple wasn't a risky buy at all, and proves that even investing heavily into an established business can pay off in droves.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And doing so wouldn't have involved gambling with your portfolio, either.

It takes money to make money in the stock market. While investing a few hundred dollars in a low-priced cryptocurrency like Shiba Inu might seem like someone's ticket to riches, it's a risky strategy. Investing larger sums of money into safer investments can accelerate the growth of a portfolio and give an investor much better odds of becoming a millionaire.

For example, if you had invested $100,000 into either Seagen (SGEN) or Apple (AAPL) a decade ago, you would already be a millionaire today. What makes these businesses so special, and are they still good buys today?

Two couples on a yacht.

Image source: Getty Images.

1. Seagen

Over the past 10 years, the S&P 500 has risen by more than 270%. As impressive as that may sound, biotech stock Seagen has skyrocketed by more than 1,000% during the same time frame. At a price of around $16 a share in 2011, a $100,000 investment would have allowed you to own 6,250 shares of the company. Today, that investment would be worth over $1.1 million. 

The healthcare company has come a long way over the past decade, growing from just $95 million in revenue in 2011 for the full year to generating more than $424 million in just its most recent quarter (for the period ending Sept. 30). The company's bladder cancer drug, Padcev, generated $95 million all on its own in the latest period, growing at a rate of 54% year over year. And that wasn't even the company's top-selling drug. That distinction belongs to the lymphoma drug Adcetris, which brought in $184.8 million in sales, generating year-over-year growth of 13%.

Despite this stunning growth, however, Seagen remains unprofitable, incurring a net loss of $293.8 million for its most recent quarter. But the company does plan to get out of the red -- it just isn't making any promises on when that will happen. And for growth investors, that's not a huge deterrent so long as the business remains on a strong trajectory and long-term profitability is possible.  Seagen's growth remains promising as the company has recently raised guidance for all of its major brands, including Adcetris and Padcev, which will combine for more than $1 billion in revenue in 2021.

When it comes to biotech stocks, all it sometimes takes is one or two drugs and a stock can take off. And you don't necessarily have to wait before there's positive news or a major approval to buy. Seagen, previously known as Seattle Genetics, had its breakthrough in August 2011 when the Food and Drug Administration (FDA) first granted accelerated approval for Adcetris for multiple indications (both relating to lymphoma). If someone bought the stock three months later, that would be roughly 10 years ago today, and they'd still have collected those amazing returns.

Although the upside for the stock may not be as high today, Seagen is also a much safer investment given its diverse portfolio. And it's still innovating with many different trials in its pipeline. In September, the FDA granted accelerated approval for Tivdak, a drug that treats metastatic cervical cancer that some analysts project could bring in peak annual revenue of more than $1 billion. Seagen has some solid drugs in its portfolio, and this cancer-fighting company continues to look like a fantastic buy for long-term investors.

2. Apple

Investors don't always need to take a chance on a risky biotech stock to earn a great return, and there's ample proof of that with Apple. The popular tech company already unveiled the iPhone in 2007 under then-CEO Steve Jobs, so it wasn't a huge risk for investors to take on at that point.

In fiscal 2011 (for the period ending Sept. 24, 2011), sales of $108 billion were 66% higher than the $65 billion the company reported a year earlier. Apple was already a fast-growing business 10 years ago and if you bought shares of the company then, it too would have gone on to rise more than 1,000%. 

Today, Apple sits at a $2.4 trillion valuation and is one of the most popular investments out there, even for billionaire investor Warren Buffett. And much has changed over the past decade. Apple has become less dependent on products and now has many different subscriptions that generate revenue for its business, including a streaming video business. In fiscal 2021 (the period ending Sept. 25), service revenue totaling $68 billion accounted for 18.7% of Apple's top line, and that segment is steadily growing; just a few years earlier in fiscal 2019, service sales of $46 billion represented 17.8% of all revenue.

The only reason not to buy Apple stock today may be due to its high valuation. It currently trades at a price-to-earnings ratio of more than 27, which is considerably higher than where it has been before the pandemic (typically around 20 times earnings or lower). But for a long-term investment, it's still an attractive option that also pays a modest dividend yield of 0.6% (below the S&P 500 average of 1.4%). If you're planning to buy and hold, it's hard to go wrong with this Buffett stock.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple and Seagen Inc. The Motley Fool recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.